KR20190037359A - 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 - Google Patents

알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Download PDF

Info

Publication number
KR20190037359A
KR20190037359A KR1020197008907A KR20197008907A KR20190037359A KR 20190037359 A KR20190037359 A KR 20190037359A KR 1020197008907 A KR1020197008907 A KR 1020197008907A KR 20197008907 A KR20197008907 A KR 20197008907A KR 20190037359 A KR20190037359 A KR 20190037359A
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
autism
disease
glyx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197008907A
Other languages
English (en)
Korean (ko)
Inventor
요셉 모스칼
Original Assignee
노오쓰웨스턴 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노오쓰웨스턴 유니버시티 filed Critical 노오쓰웨스턴 유니버시티
Publication of KR20190037359A publication Critical patent/KR20190037359A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197008907A 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Ceased KR20190037359A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US61/479,593 2011-04-27
US201161527744P 2011-08-26 2011-08-26
US61/527,744 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137031028A Division KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011211A Division KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Publications (1)

Publication Number Publication Date
KR20190037359A true KR20190037359A (ko) 2019-04-05

Family

ID=47073094

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197008907A Ceased KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020217011613A Ceased KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020207011211A Ceased KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020137031028A Ceased KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020217011613A Ceased KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020207011211A Ceased KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020137031028A Ceased KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Country Status (13)

Country Link
US (4) US20140107037A1 (enExample)
EP (2) EP3679931A3 (enExample)
JP (1) JP6035326B2 (enExample)
KR (5) KR20190037359A (enExample)
CN (2) CN108283712A (enExample)
AU (1) AU2012249397B2 (enExample)
BR (1) BR112013027554A2 (enExample)
CA (1) CA2834286A1 (enExample)
EA (2) EA201790653A1 (enExample)
HK (1) HK1258231A1 (enExample)
MX (1) MX357761B (enExample)
SG (2) SG194230A1 (enExample)
WO (1) WO2012149389A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
BR112012020142A2 (pt) 2010-02-11 2020-08-18 Northwestern University moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos.
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
PE20151438A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
DK2951183T3 (da) 2013-01-29 2019-06-03 Aptinyx Inc Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
US9828384B2 (en) 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
ES2618421T3 (es) 2013-01-29 2017-06-21 Aptinyx Inc. Moduladores espiro-lactama del receptor NMDA y usos de los mismos
SG10201810496XA (en) 2013-10-28 2018-12-28 Naurex Inc Nmda receptor modulators and prodrugs, salts, and uses thereof
CN111920412A (zh) * 2013-12-13 2020-11-13 西北大学 治疗脑部病症或鉴定与其相关的生物标记的方法
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
BR112016030375A8 (pt) * 2014-06-23 2021-07-13 Univ Northwestern uso de um composto no tratamento ou melhora da enxaqueca, no tratamento, supressão e/ou prevenção da depressão cortical e no tratamento ou melhora de uma lesão cerebral traumática
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
MX378566B (es) 2016-05-19 2025-03-11 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
KR102538803B1 (ko) 2016-08-01 2023-06-01 앱티닉스 인크. 스피로-락탐 nmda 조정제 및 그의 사용 방법
SG11201900546UA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
ATE499104T1 (de) * 2005-03-24 2011-03-15 Univ Emory Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
EP2257644B1 (en) * 2008-02-20 2015-06-24 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism
CA2740628C (en) * 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases

Also Published As

Publication number Publication date
JP6035326B2 (ja) 2016-11-30
EA201790653A1 (ru) 2017-07-31
AU2012249397A1 (en) 2013-11-07
CN103974712A (zh) 2014-08-06
US20140107037A1 (en) 2014-04-17
MX2013012526A (es) 2014-04-16
CA2834286A1 (en) 2012-11-01
KR20140043078A (ko) 2014-04-08
JP2014520072A (ja) 2014-08-21
EP2701721A4 (en) 2015-12-16
HK1258231A1 (zh) 2019-11-08
US20170049845A1 (en) 2017-02-23
EP2701721A2 (en) 2014-03-05
AU2012249397B2 (en) 2017-03-30
MX357761B (es) 2018-07-23
SG194230A1 (en) 2013-12-30
CN108283712A (zh) 2018-07-17
KR20210046843A (ko) 2021-04-28
WO2012149389A3 (en) 2014-05-08
EP3679931A3 (en) 2020-10-14
KR20180095096A (ko) 2018-08-24
EA201391581A1 (ru) 2014-05-30
EP3679931A2 (en) 2020-07-15
US20190209642A1 (en) 2019-07-11
SG10202010665YA (en) 2020-11-27
BR112013027554A2 (pt) 2016-09-06
EA029999B1 (ru) 2018-06-29
WO2012149389A2 (en) 2012-11-01
US20210169964A1 (en) 2021-06-10
KR20200043534A (ko) 2020-04-27

Similar Documents

Publication Publication Date Title
KR20190037359A (ko) 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
Tang et al. The role of GABAergic signalling in neurodevelopmental disorders
Owens et al. Is there more to GABA than synaptic inhibition?
Maden Retinoic acid in the development, regeneration and maintenance of the nervous system
Hayashi et al. Potentiation of the NMDA receptor‐mediated responses through the activation of the glycine site by microglia secreting soluble factors
ES2575684T3 (es) Agonistas de receptores de neurotrofinas y su uso como medicamentos
Mackiewicz et al. Targeting CaN/NFAT in Alzheimer’s brain degeneration
WO2015013397A2 (en) Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
Li et al. GABAB receptors in the hippocampal dentate gyrus are involved in spatial learning and memory impairment in a rat model of vascular dementia
CA3061274C (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
HK40034037A (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
JPH10508579A (ja) シナプス伝達を改善する薬
Ferrari Identification of pharmacological approaches blocking alpha-synuclein synaptic toxicity
Wheeler Functional recovery following spinal cord injury: remyelination as a therapeutic target in aging
Zhu Prenatal dysfunctions of chloride-related inhibition in lumbar motoneurons of the SOD1G93A ALS
US10398756B2 (en) Cell-permeable peptide system for treating diseases caused by glutamate excitotoxicity
Kuhn Redefining the Role of the P3 Peptide in the Amyloid Cascade Hypothesis
Balbi Group I metabotropic glutamatergic receptors regulating glutamate release and microglia phenotype in a murine model of amyotrophic lateral sclerosis
JP6526807B2 (ja) 神経伸長を促進するペプチドおよびそれらの適用
Bonifacino et al. Alterations of Synaptic Mechanisms and Excessive Glutamate Release in the Spinal Cord of SOD1G93A Mice
OA19959A (en) Synergistic compositions comprising (R)Dimiracetam (1) and (S)-Dimiracetam (2) in a non-racemic ratio
Lin Synapse maintenance and function at the mouse neuromuscular junction: Implications in diseases
Clelland A functional role of mammalian adult hippocampal neurogenesis in the normal and diseased brain

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190327

Application number text: 1020137031028

Filing date: 20131122

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190426

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190514

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200319

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190514

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200417

Application number text: 1020137031028

Filing date: 20131122